Patents by Inventor Roger K. Sunahara
Roger K. Sunahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210353626Abstract: Provided herein are modulators of beta-adrenergic receptors.Type: ApplicationFiled: April 19, 2019Publication date: November 18, 2021Inventors: Roger K. SUNAHARA, Mary J. CLARK, Brian K. KOBILKA, Cheng ZHANG, Xiangyu LIU, Peter GMEINER, Anne STÖSSEL, Harald HÜBNER, Daniela DENGLER, Markus STANEK, Brian S. SHOICHET, Magdalena KORCZYNSKA, Jacob P. MAHONEY, Jonas KAINDL
-
Publication number: 20200239534Abstract: The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G.F. Rasmussen, Sebastien Granier, Roger K. Sunahara
-
Patent number: 10626154Abstract: The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: GrantFiled: May 1, 2017Date of Patent: April 21, 2020Assignees: VIB VZW, Vrije Universiteit Brussel, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of MichiganInventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G. F. Rasmussen, Sebastien Granier, Roger K. Sunahara
-
Publication number: 20170253644Abstract: The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: May 1, 2017Publication date: September 7, 2017Applicants: VIB VZW, Vrije Universiteit Brussel, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of MichiganInventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G.F. Rasmussen, Sebastien Granier, Roger K. Sunahara
-
Patent number: 9695227Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: GrantFiled: June 21, 2012Date of Patent: July 4, 2017Assignees: Vrije Universiteit Brussel, VIB VZW, The Board of Trustees of the Leland Stanford Junior Universitv, The Regents of the University of MichiganInventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sebastian Granier, Roger K. Sunahara
-
Publication number: 20170106056Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: ApplicationFiled: December 25, 2016Publication date: April 20, 2017Applicants: The Trustees of Columbia University in the City of New York, The Regents of the University of MichiganInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovic, John J. Tesmer, Remy L. Brim
-
Patent number: 9526786Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: GrantFiled: January 28, 2014Date of Patent: December 27, 2016Assignees: The Trustee of Columbia University in the City of New York, The Regents of the University of MichiganInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovic, John J. Tesmer, Remy L. Brim
-
Publication number: 20140348813Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: ApplicationFiled: January 28, 2014Publication date: November 27, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, The Trustees of Columbia University in the City of New YorkInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovich, John J. Tesmer, Remy L. Brim
-
Publication number: 20140275487Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: June 21, 2012Publication date: September 18, 2014Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sébastien Granier, Roger K. Sunahara
-
Patent number: 8637009Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: GrantFiled: July 10, 2008Date of Patent: January 28, 2014Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of MichiganInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovich, John J. Tesmer, Remy L. Brim
-
Patent number: 8501692Abstract: The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.Type: GrantFiled: December 14, 2010Date of Patent: August 6, 2013Assignee: The Regents of the University of MichiganInventors: Roger K. Sunahara, John J. G. Tesmer, Diwahar Narasimhan, James H. Woods, Mark R. Nance, Elin Edwald
-
Publication number: 20130039900Abstract: The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.Type: ApplicationFiled: December 14, 2010Publication date: February 14, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Roger K. Sunahara, John J.G. Tesmer, Diwahar Narasimhan, James H. Woods, Mark R. Nance, Elin Edwald
-
Patent number: 8318156Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.Type: GrantFiled: July 10, 2007Date of Patent: November 27, 2012Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, University of Kentucky Research FoundationInventors: Donald W Landry, Joanne MacDonald, Shi-Xian Deng, Chang-Guo Zhan, Daquan Gao, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Victor Yang, Mei-Chuan Holden Ko, John J. Tesmer, Tien-Yi Lee, Young Min Kwon
-
Publication number: 20110142816Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal under-going a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: ApplicationFiled: July 10, 2008Publication date: June 16, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovich, John J. Tesmer, Remy L. Brim
-
Publication number: 20040229251Abstract: The present invention relates to methods of assaying nucleotide cyclase activity. In particular, the present invention relates to fluorescence-based methods of assaying guanylyl and adenylyl cyclase activity.Type: ApplicationFiled: February 13, 2004Publication date: November 18, 2004Applicant: The Regents of the University of MichignaInventors: Roger K. Sunahara, Richard R. Neubig